LONDON, Oct 19 (Reuters) - AstraZeneca Plc shares fell more than 3 percent on Friday after the European Patent Office revoked a key patent on its key asthma drug Symbicort. The move puts at risk ...
Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback